CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells
about
Status of hepatitis C virus vaccination: Recent updateHost-Targeting Agents to Prevent and Cure Hepatitis C Virus InfectionMonoclonal antibodies: Principles and applications of immmunodiagnosis and immunotherapy for hepatitis C virusHepatitis C virus: why do we need a vaccine to prevent a curable persistent infection?Genetic Diversity Underlying the Envelope Glycoproteins of Hepatitis C Virus: Structural and Functional Consequences and the Implications for Vaccine DesignAnti-infective properties of epigallocatechin-3-gallate (EGCG), a component of green teaThe hepatitis C virus glycan shield and evasion of the humoral immune responseNeutralizing antibody response to hepatitis C virusInvolvement of Tetraspanin C189 in Cell-to-Cell Spreading of the Dengue Virus in C6/36 CellsABHD5/CGI-58, the Chanarin-Dorfman Syndrome Protein, Mobilises Lipid Stores for Hepatitis C Virus ProductionIdentification of a novel drug lead that inhibits HCV infection and cell-to-cell transmission by targeting the HCV E2 glycoproteinMolecular determinants and dynamics of hepatitis C virus secretionMutations in Hepatitis C Virus E2 Located outside the CD81 Binding Sites Lead to Escape from Broadly Neutralizing Antibodies but Compromise Virus InfectivityTargeting host factors: A novel rationale for the management of hepatitis C virusCharacterization of Determinants Important for Hepatitis C Virus p7 Function in Morphogenesis by Using trans-ComplementationRNA Interference and Single Particle Tracking Analysis of Hepatitis C Virus EndocytosisReal-time imaging of hepatitis C virus infection using a fluorescent cell-based reporter systemNovel Function of CD81 in Controlling Hepatitis C Virus ReplicationAn alpaca nanobody inhibits hepatitis C virus entry and cell-to-cell transmissionSeed Sequence-Matched Controls Reveal Limitations of Small Interfering RNA Knockdown in Functional and Structural Studies of Hepatitis C Virus NS5A-MOBKL1B InteractionA novel small molecule inhibitor of hepatitis C virus entryA novel monoclonal anti-CD81 antibody produced by genetic immunization efficiently inhibits Hepatitis C virus cell-cell transmissionHepatitis C virus cell-cell transmission and resistance to direct-acting antiviral agentsNaturally occurring antibodies that recognize linear epitopes in the amino terminus of the hepatitis C virus E2 protein confer noninterfering, additive neutralizationExploration of acetanilide derivatives of 1-(ω-phenoxyalkyl)uracils as novel inhibitors of Hepatitis C Virus replicationHepatitis C virus cell entry: a target for novel antiviral strategies to address limitations of direct acting antivirals.Conserved glycine 33 residue in flexible domain I of hepatitis C virus core protein is critical for virus infectivity.Cell-cell contact-mediated hepatitis C virus (HCV) transfer, productive infection, and replication and their requirement for HCV receptors.Different requirements for scavenger receptor class B type I in hepatitis C virus cell-free versus cell-to-cell transmissionAdaptation of hepatitis C virus to mouse CD81 permits infection of mouse cells in the absence of human entry factors.Hepatitis C virus hypervariable region 1 modulates receptor interactions, conceals the CD81 binding site, and protects conserved neutralizing epitopes.Mutations within a conserved region of the hepatitis C virus E2 glycoprotein that influence virus-receptor interactions and sensitivity to neutralizing antibodies.Production of infectious hepatitis C virus by using RNA polymerase I-mediated transcription.Completion of hepatitis C virus replication cycle in heterokaryons excludes dominant restrictions in human non-liver and mouse liver cell lines.Requirement of cellular DDX3 for hepatitis C virus replication is unrelated to its interaction with the viral core protein.Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantationExosomes from hepatitis C infected patients transmit HCV infection and contain replication competent viral RNA in complex with Ago2-miR122-HSP90.The Humoral Immune Response to HCV: Understanding is Key to Vaccine Development.Clinical development of monoclonal antibody-based drugs in HIV and HCV diseasesBroadly neutralizing antibodies abrogate established hepatitis C virus infection
P2860
Q26774612-1E9001F1-6B7B-4B67-AC48-95994E400F1FQ26779128-956617F1-78EE-4758-A2F7-ACDAE989955BQ26783378-9A35D48E-CCE5-4C2D-937A-AF3415BCE2FDQ26799141-E9AD2526-5B04-4149-B926-2640675E14AEQ26801759-B09B4D82-C2BA-449F-90F0-0B1D6F0937E8Q26852556-3D1CE641-0E9A-4390-8078-278B833B7735Q27023390-77F06920-30C4-4BAE-B6D0-86608BFA571CQ27027484-90BEFF36-EFE2-4936-856B-495586C3E85FQ27304407-57C1AA05-52B7-4CA0-B18D-40E2F6D2C0ABQ27314827-6812B6F5-6BA9-4E50-89B9-DBD90E50848BQ27333881-922468E8-5F04-432F-9076-CF9432CF5195Q27347838-F7209645-73B6-4469-837A-B5EF7BFB74C1Q27488430-2379B990-E1F1-4DA0-BB7B-E273F91253F2Q27488999-ABFA7FBD-1A46-4EC0-BEC6-CE56FBACD97DQ27490303-A3D2E48E-6348-465F-9A16-0A9B39A0DEEFQ27490501-69745419-466B-4876-A49E-A88A13C5755CQ27490982-F3501E96-81A0-4879-8689-19B7CC42FC37Q27491131-23DA2DF3-3AD1-4F66-9611-3F224D71D093Q27684354-6C9E5BAE-27F3-4047-B149-C37220DE77C9Q27684710-AE917C50-395A-47BD-A9E1-51CC2939E03FQ28475468-D6342208-92A4-4545-B2AD-B14363191427Q28488372-E042C4C5-4138-4203-AB3C-F9DD4CCDB27EQ28538891-CF8BD5E4-33EF-4938-A9A5-70469F4AB80FQ28731355-06DCF28D-BFC1-4E9C-AC72-130635A1680DQ28830384-BC571FF5-BC3B-4EC4-A977-A135F516E3DEQ30386551-2BEC3B97-1BCC-43CB-A1A7-4B2A50713D12Q30409246-56E72EA9-4C48-4DBA-AA8D-40D28766645BQ30541731-74A3D907-CC69-4AE9-B133-27A1C0F678B9Q30541733-56C10253-07D9-4754-A7CF-C7A206D09012Q33628805-201C92A3-0291-4B76-9E20-87E9D2DEA2B3Q33877342-50C9BF9E-5190-401F-B975-DA862C186EC3Q33877381-AC72F3FF-19DB-4076-B163-5CD2DED50A6AQ33877391-276620E2-079A-4A73-9306-C66F225DCE81Q33892350-B8D6DB07-8857-427A-B7FF-182DE8F58635Q33910745-3D6898B6-572C-454F-90CF-CD8EA75C9C39Q34096483-B255CB31-4DCA-43DD-A6C3-9B8495AE7C35Q34282491-62BDB609-5139-4ECC-942E-C73627D99699Q34481429-557C5E96-B648-4E86-84AB-EE046C561671Q34536782-2CC47C61-2FA4-449B-A7E1-92650212A222Q35032263-099341D3-4C8B-4D1D-AF9C-796DBA0634BC
P2860
CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells
description
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2009
@ast
im Januar 2009 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 2009/01/01)
@sk
vědecký článek publikovaný v roce 2009
@cs
wetenschappelijk artikel (gepubliceerd op 2009/01/01)
@nl
наукова стаття, опублікована в січні 2009
@uk
مقالة علمية (نشرت عام 2009)
@ar
name
CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells
@ast
CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells
@en
CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells
@nl
type
label
CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells
@ast
CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells
@en
CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells
@nl
prefLabel
CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells
@ast
CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells
@en
CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells
@nl
P2093
P2860
P3181
P356
P1476
CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells
@en
P2093
Allan G N Angus
Ania M Owsianka
Arvind H Patel
Charles M Rice
George Koutsoudakis
Jeroen Witteveldt
Julia Bitzegeio
Steven K H Foung
Thomas Pietschmann
Zhen-Yong Keck
P2860
P3181
P356
10.1099/VIR.0.006700-0
P407
P577
2009-01-01T00:00:00Z